Sinopharm Dental Completes Series A Funding Round Led by China Renaissance Capital, Advances Integrated Oral Healthcare Empowerment Platform
On February 9, VCBeat (WeChat ID: vcbeat) learned at the earliest opportunity that,China’s New Force in Dental “Midstream Integration + Innovation”: Sinopharm Dental Announces Completion of Series A FinancingThis round of financing was led by China Renaissance New Economy Fund, an affiliate of China Renaissance, with DT Capital participating as a co-investor. China Renaissance served as the exclusive financial advisor for this financing round.
Sinopharm Dental, established in October 2017, represents a strategic initiative by Sinopharm Capital to enter the Chinese dental market through its “integration of capital and business operations” strategy. Its objective is to build a dental health ecosystem tailored to China’s dental industry by fully leveraging the synergy between capital and industry resources.
The oral health industry is a medical subsector that has garnered significant market attention.Benefiting from the introduction of relevant policies in recent years, a large number of physicians have joined the entrepreneurial wave. Data from Qichacha shows that 17,100 new dental medical-related enterprises were registered in China in 2020. According to the development experience of the U.S. dental industry, the dental healthcare market tends to grow rapidly when a country’s per capita GDP ranges between $6,000 and $10,000.China's economy has now reached a comparable level, and the oral care industry is entering a phase of sustained, rapid growth.
Regarding the details of this round of financing, VCBeat conducted an exclusive interview with Lv Sang, Director and General Manager of Sinopharm Stomatology, to analyze the reasons behind Sinopharm Stomatology’s appeal to investors from multiple perspectives.
One of Sinopharm Dental’s core missions is to support dentists in launching their own practices by identifying and addressing their needs throughout the entrepreneurial journey.This reflects the demands of 100,000 downstream dental clinics in China, and even more so, those of the 170,000 practicing dentists behind them.
To achieve integrated innovation in the midstream sector, participants must have a thorough understanding of midstream distribution processes. In this regard, Mr. Wu Aimin, President of Sinopharm Capital and Chairman of Sinopharm Dental, has personally witnessed the transformations in the pharmaceutical industry over the past two decades.In Mr. Wu Aimin’s view, with the rise in national economic levels and growing demand for health care, China’s oral health market holds immense potential for development, and leading enterprises are bound to emerge in this sector.
To this end, benchmarking against U.S. dental giants Henry Schein and Patterson, and targeting the needs and gaps in the oral care industry, Sinopharm Capital began preparing for mergers and acquisitions in the dental sector in 2016. After thorough evaluation of the industry, it ultimately established the strategic direction of “building a one-stop oral care empowerment platform with full industry chain coverage,” and officially founded Sinopharm Dental in 2017.
“Amid the wave of scale effects brought about by the consolidation of pharmaceutical distribution enterprises, Sinopharm has leapt to become the leading domestic pharmaceutical distributor through mergers and acquisitions, firmly securing its place on the Fortune Global 500 list.”Lu Sang, Director and General Manager of Sinopharm Dental, stated that the dental industry bears strong resemblance to the pharmaceutical industry of over a decade ago, which allows Sinopharm Dental to leverage its transferable experience.
Certainly, when it comes to the specific industry of oral health,Merely having experience in mergers and acquisitions (M&A) integration is far from sufficient; it also requires deep cultivation of the dental industry.Based on this, Sinopharm Dental has proposed an “Integration + Innovation” development model to drive empowerment and innovation within the dental industry.
In terms of integration, after more than three years of efforts, Sinopharm Dental has currently established 16 subsidiaries and 8 sub-subsidiaries in major provinces and cities across China, with its distribution business for dental consumables and equipment covering all major provinces in the country.
In terms of innovation, Sinopharm Dental’s deeply cultivated Chinese-style DSO model has achieved strong pilot results, with its one-stop empowerment platform beginning to take shape.“Sinopharm Dental DSO business provides one-stop operational services for private dental clinics, including but not limited to supply chain finance, clinic medical engineering design, B2B e-commerce, licensed practitioner protection, and patient referral,” said Lv Sang.
Under the blueprint for building an oral health ecosystem,Sinopharm Dental has entered the consumer business sector by establishing “Ai Chi Yi,” a professional consumer dental brand that integrates high-quality resources from the insurance industry, innovative payment solutions, personal oral care products, and dental clinics., providing the best options for oral prevention, diagnosis and treatment, and daily care to traffic entry points such as insurance companies, large enterprise clients, employee benefits programs, and points redemption platforms.
“The unique characteristics of the dental industry have led to diverse business models in the midstream sector. Sinopharm Dental, positioned in the midstream, fosters a win-win development landscape by connecting upstream, midstream, and downstream partners, thereby supporting the next golden 20 years of the dental industry. Since its establishment in 2017, Sinopharm Dental has steadily expanded its team. These achievements would not have been possible without the strong support from Sinopharm Capital, nor without the dedicated efforts of all team members and partners. We hereby express our heartfelt gratitude. We also extend our appreciation to the new investors for their recognition.”Upon completion of the financing, the company will continue to drive model enhancement and innovation in the dental industry, optimize industry efficiency, expand market scale, and improve oral health for the Chinese public..” said Mr. Lv Sang, Director and General Manager of Sinopharm Dental.
As the lead investor in this round, Bao Fan, Chairman of China Renaissance Holdings Limited, Founding Partner and Chief Investment Officer of its fund, stated, “We are honored to join the board of directors of Sinopharm Dental and remain bullish on the company’s long-term growth potential.”The dental industry represents a close integration of medicine and aesthetics, thereby exhibiting strong consumer-driven characteristics.“On the one hand, the younger generation’s pursuit of aesthetics and quality of life has driven the oral care market to exceed RMB 100 billion, offering substantial potential for high-speed growth. On the other hand, the continued fragmentation of the industry structure has increasingly highlighted the value of consolidating midstream players in the oral care sector. We believe that Sinopharm Oral Care, as one of the most investment-worthy platforms in the industry today, is well-positioned to enhance and reshape the efficiency and value chain of the oral care sector. China Renaissance will provide long-term support to the company, and we look forward to jointly building an industry powerhouse to empower industrial upgrading.”
Mr. Shao Jun, Founding Partner of DT Capital Partners, stated: “The oral care industry boasts a vast market, and the upgrading and integration of its industrial chain is an inevitable trend.Leveraging Sinopharm’s brand strength and resource advantages, Sinopharm Dental boasts a professional, mature team with extensive industry experience. Positioned in China’s rapidly expanding midstream dental sector, the company bridges the fragmented upstream and downstream segments, empowering its regional subsidiary leaders. It has achieved integration and enhancement across culture, systems, and data, holding immense future potential. DT Capital Partners is committed to supporting Sinopharm Dental’s accelerated growth, aiming to foster rapid development through an “integration + innovation” model. The goal is to build a large-scale industrial ecosystem, establish Sinopharm Dental as a leading enterprise in the oral care market at an early stage, and ultimately improve the oral health of the general public.
“Sinopharm Dental is a pioneer in integrating the midstream dental sector, with extensive experience in consolidation and M&A. Additionally,”Oral care products play a crucial role in product promotion, education, and after-sales service, resulting in a significant competitive moat.“The dental industry has undergone a phoenix-like rebirth in the post-pandemic era. We are honored to have assisted Sinopharm Dental in completing this financing round and will continue to serve as its long-term partner in the capital markets, witnessing the birth of ‘China’s Henry Schein,’” said Xie Yijing, Managing Director and Head of the Healthcare and Life Sciences Group at China Renaissance Holdings.
It is reported that, with the support of this round of financing, Sinopharm Dental will continue to lead the industry’s “integration + innovation” transformation, unlocking win-win value across the upstream, midstream, and downstream segments of the entire dental care industry chain.